Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $72.00 at Wells Fargo & Company

Key Points

• Wells Fargo raised Definium Therapeutics’ price target to $72 from $68 and maintained an “overweight” rating, implying 68.26% potential upside from the prior close.
• Analyst sentiment remains broadly positive: MarketBeat reports a consensus “Buy” rating and $58.69 price target, while recent firms including JonesTrading, Baird and Needham also raised targets. However, HC Wainwright lowered longer-term EPS forecasts, reflecting expectations for continued losses.
• Definium’s shares opened at $42.79, near their $49.70 12-month high, but the company reported quarterly EPS of negative $1.44—well below the expected negative $0.55. Insiders have sold 48,096 shares worth about $2.17 million over the past 90 days.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) had its price objective upped by Wells Fargo & Company from $68.00 to $72.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Wells Fargo & Company's price target indicates a potential upside of 68.26% from the stock's previous close.

DFTX has been the subject of a number of other research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Definium Therapeutics in a research note on Friday, July 17th. Canaccord Genuity Group set a $58.00 price target on shares of Definium Therapeutics and gave the stock a "buy" rating in a research note on Tuesday, June 30th. JonesTrading upped their price target on shares of Definium Therapeutics from $61.00 to $74.00 and gave the company a "buy" rating in a research report on Wednesday, June 24th. Citigroup reaffirmed a "buy" rating on shares of Definium Therapeutics in a research note on Monday, June 22nd. Finally, Royal Bank Of Canada reiterated an "outperform" rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $58.69.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $42.79 on Thursday. The stock has a market cap of $4.27 billion, a P/E ratio of -12.48 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The business's 50-day moving average price is $39.06 and its two-hundred day moving average price is $26.52. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). As a group, equities analysts predict that Definium Therapeutics will post -2.81 EPS for the current fiscal year.

Insider Activity at Definium Therapeutics

In related news, insider Mark Sullivan sold 13,008 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares of the company's stock, valued at $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Brandi Roberts sold 3,013 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the sale, the chief financial officer directly owned 209,487 shares in the company, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its stake in Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock worth $25,000 after purchasing an additional 2,003 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of Definium Therapeutics by 56.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock valued at $55,000 after buying an additional 3,020 shares in the last quarter. Caxton Associates LLP bought a new stake in shares of Definium Therapeutics during the 3rd quarter valued at $126,000. Mercer Global Advisors Inc. ADV grew its position in shares of Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock worth $259,000 after buying an additional 2,079 shares during the period. Finally, Scientech Research LLC purchased a new stake in shares of Definium Therapeutics in the 3rd quarter worth about $286,000. Hedge funds and other institutional investors own 27.91% of the company's stock.

Definium Therapeutics News Roundup

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported positive topline results from its Phase 3 Voyage study. DT120 ODT produced a 5.4-point improvement versus placebo on the Hamilton Anxiety Rating Scale, supporting the drug’s efficacy in GAD. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: The results represent the second positive Phase 3 study for DT120, increasing confidence in the treatment’s potential across indications and driving significant investor interest. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: Robert W. Baird raised its price target from $57 to $75 and kept an “outperform” rating. Needham also lifted its target from $50 to $66 and assigned a “buy” rating, signaling greater analyst confidence in DFTX’s pipeline and valuation. Analyst price-target changes
• Neutral Sentiment: Trading in DFTX was briefly halted for “news pending” before the Phase 3 announcement, reflecting the market sensitivity surrounding the clinical update.
• Negative Sentiment: HC Wainwright reduced its 2026 and 2027 EPS forecasts and lowered longer-term estimates, including FY2028 through FY2030. The revisions indicate expectations for continued losses and potentially slower profitability, although this concern was outweighed by the clinical data.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source